期刊文献+

血清鳞状上皮细胞癌抗原、癌抗原125、癌抗原19-9在宫颈癌及癌前病变的表达及意义 被引量:2

下载PDF
导出
摘要 目的:分析宫颈癌及癌前病变中血清鳞状上皮细胞癌抗原(SccAg)、癌抗原125(CA125)、癌抗原19-9(CA19-9)的表达情况,以提供早期宫颈癌及癌前病变的早期检测指标,早发现早治疗宫颈癌及癌前病变,提高治愈率。方法:测定、比较2010年3月-2012年3月于本科就诊、确诊的102例宫颈上皮内瘤变(CIN)和39例宫颈癌患者及47例健康者的SccAg、CA125、CA19-9水平。结果:健康对照组SccAg、CA125、CA19-9水平均在正常范围内,研究组中CIN、宫颈癌患者的SccAg、CA125、CA19-9水平均高于对照组(P<0.05);CIN、宫颈癌患者SccAg、CA125水平与对照组相比亦具有统计学意义(P<0.05)。CINⅠ级、Ⅱ级、Ⅲ级患者的SccAg、CA19-9水平比较差异均有统计学意义(P<0.05)。Ⅰ-Ⅱa期、Ⅱb-Ⅲ期宫颈癌患者各指标比较差异均有统计学意义(P<0.05),Ⅱb-Ⅲ期水平均高于Ⅰ-Ⅱa期;不同分化程度各指标水平比较差异有统计学意义(P<0.05)。结论:血清SccAg、CA125、CA19-9可作为宫颈癌及癌前病变的早期检测指标,其数值的变化提示了宫颈癌及癌前病变患者的病情;血清SccAg、CA125、CA19-9肿瘤标志物能为患者的辅助诊断提供指导信息。
出处 《中国医学创新》 CAS 2012年第36期24-25,共2页 Medical Innovation of China
  • 相关文献

参考文献6

  • 1Bruijn H W,Duk J M,Van der Zee A G. The clinical value of squamous cell carcinoma antigen in cancer of the uterine cervix[J].Tumour Biology,1998,(06):505-516.
  • 2Borras G,Molina R,Xercavins J. Tumor antigens CA19-9,CA 125,and CEA in carcinoma of the uterine cervix[J].Gynecologic Oncology,1995,(02):205-211.
  • 3马丁,奚玲.宫颈癌专题讨论──宫颈癌流行病学及病因学研究进展[J].实用妇产科杂志,2001,17(2):61-62. 被引量:212
  • 4Kato H,Torigoe T. Radioimmunoassay for tumor antigen of human cervical squamous cell cacinoma[J].Cancer,1977,(04):1621.
  • 5Nawata S,Murakami A,Torii M. Different expression patterns of intact forms of squamous cell carcinoma antigens between normal and malignant cervical squamous epithelial tissues:nondenaturing polyacryl-amide gel electrophoretic analysis[J].Oncology Reports,2006,(02):399.
  • 6Shimada Y,Watanabe G,Kawamura J. Clinical significance of osteopontin in esophageal squamous cell carcinoma:comparison with common tumor markers[J].Oncology(Basel),2005,(02):285.

共引文献211

同被引文献25

  • 1Lin CY, Tsa i PH,Kandaswami CC,et al.Matrix mcta|loprotcinas-9 cooperates with transeript ion factor snail to induce epifllelial-mesenchymal transition[J]. Cancer Sci,201 1,102(4):815-827.
  • 2Roomi M W,Montcrrcy J C, Kalinovsky T, et al.ln vitro modulation of MMP-2 and /v IMP-9 in human cervical and ovarian cancer cell lines by cytokines, inducers and inhibitors[J].Oncol Rcp, 2010,23:605-615.
  • 3Hanna T P,Shafiq J,Delaney G P,et al.The population benefit of radiotherapy for cervical cancer:local control and survival estimates for optimallyutilized radiotherapy and chemoradiation[J].Radiother Oncol,2015,114(3):389-394.
  • 4Heo C K,Bahk Y Y,Cho E W.Tumor associated autoantibodies as diagnostic and prognostic biomarker[J].BMB Rep,2012,45(12):677-685.
  • 5Zaenker P,Ziman M R.Serologic autoantibodies as diagnostic cancer biomarkers-a review[J].Cancer Epidemiol Biomarkers Prev,2013,22(12):2161-2181.
  • 6Liu W,De La Torre I G,Gutiérrez-Rivera M C,et al.Detection of autoantibodies to multiple tumor-associated antigens(TAAs)in theimmunodiagnosis of breast cancer[J].Tumour Biol,2015,36(2):1307-1312.
  • 7Fernández M F,Maroun M C.Autoantibodies in breast cancer[J].Adv Clin Chem,2014,64(1):221-240.
  • 8Kuglik P,Kasikova K,Smetana J,et al.Molecular cytogenetic analyses of h TERC(3q26)and MYC(8q24)genes amplifications in correlation with oncogenic human papillomavirus infection in Czech patients with cervicalintraepithelial neoplasia and cervical carcinomas[J].Neoplasma,2015,62(1):130-139.
  • 9Albihn A,Johnsen J I,Henriksson M A.MYC in oncogenesis and as a target for cancer therapies[J].Adv Cancer Res,2010,107(4):163-224.
  • 10Xu Y W,Peng Y H,Chen B,et al.Autoantibodies as potential biomarkers for the early detection of esophageal squamous cell carcinoma[J].Am J Gastroenterol,2014,109(1):36-45.

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部